Inhaled insulins: Their potential in the treatment of diabetes mellitus

Treatments in Endocrinology

Volumn 4, Issue 3, 2005, Pages 131-138

  Harsch, Igor Alexander ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN; TECHNOSPHERE;

AQUEOUS SOLUTION; BREATHING; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG PACKAGING; DRUG SAFETY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LUNG; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; DIABETES MELLITUS; HUMANS; INSULIN; SMOKING;

EID: 23044490100     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200504030-00001     Document Type: Review

References (52)

1. Gänsslein M. Über Inhalation von Insulin. Klin Wochenschr 1925; 4: 71
2. Heubner W, de Jongh SE, Laquer E. Über Inhalation von Insulin. Klin Wochenschr 1924; 3: 2342-3
3. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000; 23: 754-8
4. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002 Sep; 26 Suppl. 3: S18-24
5. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001; 357: 331-5
6. Capelleri JC, Gerber RA, Kourides IA, et al. Development and factor analysis of a questionnaire to measure patient satisfaction with injected and inhaled insulin for type 1 diabetes. Diabetes Care 2000; 23: 1799-803
7. Skyler JS, for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial [abstract]. Diabetes 2002; 51 Suppl. 2: A134
8. Cefalu WT, Skyler JS, Kourides IA, et al. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med 2001; 134: 203-7
9. Weiss SR, Cheng SL, Kourides IA, et al. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003; 163: 2277-82
10. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group. European Diabetes Epidemiology Group. Diabetes Epidemiolo-gy: Collaborative analysis Of Diagnostic criteria in Europe. Lancet 1999; 354: 617-21
11. DeFronzo R, for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared with rosiglitazone in type 2 diabetes patients not optimally controlled on diet and exercise: results of a 3-month, randomized, comparative trial [abstract]. Diabetes 2003; 52 Suppl. 1: A38
12. Cappelleri JC, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther 2002; 24: 552-64
13. Gerber RA, Cappelleri JC, Kourides IA, et al. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001; 24: 1556-9
14. Skyler J, for the Exubera® Phase II Study Group. Sustained long-term efficacy and safety of inhaled insulin during 4 years of continuous therapy [poster no. 486-P]. Diabetes 2004; 53 Suppl. 2: A115
15. An B, Reinhardt R. Breath holding is not required for pulmonary administration of insulin by the AERx™ insulin diabetes management system [abstract]. Diabetes 2002; 51 Suppl. 2: A127
16. Insulin inhalation. Drugs RD 2004; 5: 46-9
17. Brunner GA, Balent B, Ellmerer M, et al. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients. Diabetologia 2001; 44: 305-8
18. Hermansen K, Ronnemaa T, Petersen AH, et al. Intensive therapy with inhaled insulin via the AERx™ insulin diabetes management system: a 12-week proofof-concept trial in patients with type 2 diabetes. Diabetes Care 2004; 27: 162-7
19. Cramer J, Okikawa J, Clauson P. Compliance with inhaled insulin treatment using AERx™ iDMS [abstract]. Diabetes 2003; 52 Suppl. 1: A103
20. Henry RR, Mudaliar S, Chu N, et al. Young and elderly type 2 diabetic patients inhaling insulin with the AERx™ insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J Clin Pharmacol 2003; 43: 1228-34
21. Henry RR, Mudaliar SR, Howland III WC, et al. Inhaled insulin using the AERx™ insulin diabetes management system in healthy and asthmatic subjects. Dia-betes Care 2003; 26: 764-9
22. Himmelmann A, Jendle J, Mellen A, et al. The impact of smoking on inhaled insulin. Diabetes Care 2003; 26: 677-82
23. Cappelleri JC, Gerber RA, Bell-Farrow AD, et al. Improved patient satisfaction with inhaled insulin in subjects with type 2 diabetes mellitus: results from a multicenter randomized trial [abstract]. Diabetes 2000; 49 Suppl. 1: A100
24. Gerber R, Cappelleri JC, Bell-Farrow AD, et al. Improved patient satisfaction with inhaled insulin in subjects with type 1 diabetes mellitus after one year: results from a multicenter extension trial [abstract]. Diabetes 2000; 49 Suppl. 1: A100
25. Heise T, Rave K, Bott S, et al. Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin [abstract]. Diabetes 2000; 39 Suppl. 1: A10
26. Farr SJ, McElduff A, Mather LE, et al. Pulmonary insulin administration using the AERx™ system: physiological and biochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2000; 2: 185-97
27. McElduff A, Clauson P, Uy C, et al. Pulmonary absorption profiles of insulin during and after an upper respiratory tract infection in healthy volunteers using the AERx™ insulin diabetes management system: an open labeled cross-over study in healthy volunteers [abstract]. Diabetes 2002; 51 Suppl. 2: A107
28. Sha S, Becker RHA, Willavaise SA. The effect of smoking cessation on the absorption of inhaled insulin (Exubera®) [abstract]. Diabetes 2002; 51 Suppl. 1: A538
29. Gale EAM. Two cheers for inhaled insulin. Lancet 2001; 357: 324-5
30. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabet Med 2003; 20: 886-98
31. Nathan DM. Inhaled insulin for type 2 diabetes: solution or distraction? Ann Intern Med 2001; 134: 242-5
32. Fineberg SE, Schatz D, Krasner A, et al. Insulin antibody binding in clinical studies of inhaled insulin (Exubera®) in patients with type 1 or type 2 diabetes [poster]. American Association of Clinical Endocrinologists' 12th annual meeting and Clinical Congress; 2003 May 14; San Diego
33. Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992; 8: 179-96
34. Kjellstrom T, Malmquist J. Insulin effects on collagen and protein production in cultured human skin fibroblasts from diabetic and non-diabetic subjects. Horm Metab Res 1984; 16: 168-73
35. Rom WN, Basset P, Fells GA, et al. Alveolar macrophages release an insulin-like growth factor I-type molecule. J Clin Invest 1988; 82: 1685-93
36. Bittermann PB, Rennard RI, Hunninghake GW, et al. Human alveolar macrophage growth factor for fibroblasts. J Clin Invest 1982; 70: 808-22
37. Goldstein RH, Polkis CF, Pilch PF, et al. Stimulation of collagen formation by insulin and insulin-like growth factor I in cultures of human lung fibroblasts. Endocrinology 1989; 124: 964-70
38. Valente AXCN, Langer R, Stone HA, et al. Recent advances in the development of an inhaled insulin product. BioDrugs 2003; 17: 9-17
39. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Diabetes Care 1998; 21: 1414-31
40. Pfützner A, Sommerer K, Meyer T, et al. Lung distribution of radiolabeled Technosphere™/insulin [abstract]. Diabetes 2003; 52 Suppl. 2: A107
41. Steiner S, Pfützner A, Wilson BR, et al. Technosphere™/ insulin: proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002; 110: 17-21
42. Pfützner A, Mann AE, Steiner SS. Technosphere™/insulin: a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002; 4: 589-94
43. Pfützner A, Rave K, Heise T, et al. Inhaled Technosphere™/ insulin results in low variability in metabolic action in type 2 diabetic patients [abstract]. Exp Clin Endocrinol Diabetes 2000; 5 Suppl. 1: A113
44. Pfützner A, Pohlmann T, Hoberg C, et al. Variability of insulin absorption after subcutaneous and pulmonary application in patients with type 2 diabetes [abstract]. Diabetes 2002; 51 Suppl. 2: A47
45. Fishman RS, Guinta D, Chambers F, et al. Insulin administration via the Aero-dose™ inhaler: comparison to subcutaneously injected insulin [abstract]. Dia-betes 2000; 49 Suppl. 1: A9
46. Kim D, Mudaliar S, Chinnapongse S, et al. Dose-response relationships of inhaled insulin delivered via the Aerodose™ insulin inhaler and subcutaneously inject-ed insulin in patients with type 2 diabetes. Diabetes Care 2003; 26: 2842-7
47. Perera AD, Kapitza C, Nosek L, et al. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose™ insulin inhaler in patients with type 2 diabetes. Diabetes Care 2002; 25: 2276-81
48. Edwards DA, Ben-Jeriba A, Eskew ML, et al. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998; 85: 379-85
49. Hrkach J, Batycky R, Chen D, et al. AIR® insulin: complete diabetes therapy via inhalation of fast-acting and slow-acting dry powder aerosols [abstract]. Diabetes 2000; 49 Suppl. 1: A9
50. Pna A, Chan C, Loh MT, et al. Effects of smoking (immediate and delayed), abstinence, nicotine replacement therapy and smoking resumption on pulmonary insulin pharmacokinetics and glucodynamics [poster no. 476-P]. Diabetes 2004; 53 Suppl. 2: A113
51. Kwon J-H, Lee B-H, Lee J-J, et al. Insulin microcrystal for pulmonary drug delivery [abstract]. Diabetes 2002; 51 Suppl. 2: A105
52. Leach C, Kuo M-C, Perkins K, et al. Dry powder formulation of inhaled PEG-insulin yields prolonged systemic activity in dogs [abstract]. Diabetes 2003; 52 Suppl. 1: A105